Comparison Overview

Glenmark Pharmaceuticals

VS

Novartis

Glenmark Pharmaceuticals

Glenmark House, B.D.Sawant Marg,, Chakala, Andheri (East), Mumbai, Maharashtra, IN, 400099
Last Update: 2025-12-09

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 14,411
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Novartis

Novartis Campus, Basel, Baselstadt, 4002, CH
Last Update: 2025-12-09
Between 800 and 849

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 78,879
Subsidiaries: 38
12-month incidents
0
Known data breaches
0
Attack type number
1

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/glenmark-pharmaceuticals.jpeg
Glenmark Pharmaceuticals
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/novartis.jpeg
Novartis
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Glenmark Pharmaceuticals
100%
Compliance Rate
0/4 Standards Verified
Novartis
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Glenmark Pharmaceuticals in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Novartis in 2025.

Incident History — Glenmark Pharmaceuticals (X = Date, Y = Severity)

Glenmark Pharmaceuticals cyber incidents detection timeline including parent company and subsidiaries

Incident History — Novartis (X = Date, Y = Severity)

Novartis cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/glenmark-pharmaceuticals.jpeg
Glenmark Pharmaceuticals
Incidents

No Incident

https://images.rankiteo.com/companyimages/novartis.jpeg
Novartis
Incidents

Date Detected: 06/2022
Type:Cyber Attack
Motivation: Financial Gain
Blog: Blog

FAQ

Novartis company demonstrates a stronger AI Cybersecurity Score compared to Glenmark Pharmaceuticals company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Novartis company has historically faced a number of disclosed cyber incidents, whereas Glenmark Pharmaceuticals company has not reported any.

In the current year, Novartis company and Glenmark Pharmaceuticals company have not reported any cyber incidents.

Neither Novartis company nor Glenmark Pharmaceuticals company has reported experiencing a ransomware attack publicly.

Neither Novartis company nor Glenmark Pharmaceuticals company has reported experiencing a data breach publicly.

Novartis company has reported targeted cyberattacks, while Glenmark Pharmaceuticals company has not reported such incidents publicly.

Neither Glenmark Pharmaceuticals company nor Novartis company has reported experiencing or disclosing vulnerabilities publicly.

Neither Glenmark Pharmaceuticals nor Novartis holds any compliance certifications.

Neither company holds any compliance certifications.

Novartis company has more subsidiaries worldwide compared to Glenmark Pharmaceuticals company.

Novartis company employs more people globally than Glenmark Pharmaceuticals company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Glenmark Pharmaceuticals nor Novartis holds SOC 2 Type 1 certification.

Neither Glenmark Pharmaceuticals nor Novartis holds SOC 2 Type 2 certification.

Neither Glenmark Pharmaceuticals nor Novartis holds ISO 27001 certification.

Neither Glenmark Pharmaceuticals nor Novartis holds PCI DSS certification.

Neither Glenmark Pharmaceuticals nor Novartis holds HIPAA certification.

Neither Glenmark Pharmaceuticals nor Novartis holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

LibreChat is a ChatGPT clone with additional features. In versions 0.8.0 and below, there is no handler for JSON parsing errors; SyntaxError from express.json() includes user input in the error message, which gets reflected in responses. User input (including HTML/JavaScript) can be exposed in error responses, creating an XSS risk if Content-Type isn't strictly enforced. This issue does not have a fix at the time of publication.

Risk Information
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:L/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

LibreChat is a ChatGPT clone with additional features. In versions 0.8.0 and below, when creating prompts, JSON requests are sent to define and modify the prompts via PATCH endpoint for prompt groups (/api/prompts/groups/:groupId). However, the request bodies are not sufficiently validated for proper input, enabling users to modify prompts in a way that was not intended as part of the front end system. The patchPromptGroup function passes req.body directly to updatePromptGroup() without filtering sensitive fields. This issue is fixed in version 0.8.1.

Risk Information
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:L/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

LibreChat is a ChatGPT clone with additional features. In versions 0.8.0 and below, when a user posts a question, the iconURL parameter of the POST request can be modified by an attacker. The malicious code is then stored in the chat which can then be shared to other users. When sharing chats with a potentially malicious “tracker”, resources loaded can lead to loss of privacy for users who view the chat link that is sent to them. This issue is fixed in version 0.8.1.

Risk Information
cvss4
Base: 8.6
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:H/VI:H/VA:N/SC:L/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

MaxKB is an open-source AI assistant for enterprise. Versions 2.3.1 and below have improper file permissions which allow attackers to overwrite the built-in dynamic linker and other critical files, potentially resulting in privilege escalation. This issue is fixed in version 2.4.0.

Risk Information
cvss3
Base: 8.8
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
Description

MaxKB is an open-source AI assistant for enterprise. In versions 2.3.1 and below, the tool module allows an attacker to escape the sandbox environment and escalate privileges under certain concurrent conditions. This issue is fixed in version 2.4.0.

Risk Information
cvss3
Base: 8.8
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H